Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (171-180 of 187) with videos related to

Pageof 19
Sort By:
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Blood Advances|January 17, 2024
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trialMaria Gabriella Mazzucconi, Francesco Rodeghiero, Giuseppe Avvisati, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Leukemia|May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control studyTiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Oncotarget|April 22, 2017
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratoriesMargherita Perricone, Francesca Palandri, Emanuela Ottaviani, et al.
Blood|December 24, 2019
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control studyValerio De Stefano, Arianna Ghirardi, Arianna Masciulli, et al.
Blood Cancer Journal|March 15, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Pageof 19

Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Blood Advances|January 17, 2024
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trialMaria Gabriella Mazzucconi, Francesco Rodeghiero, Giuseppe Avvisati, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Leukemia|May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control studyTiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Oncotarget|April 22, 2017
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratoriesMargherita Perricone, Francesca Palandri, Emanuela Ottaviani, et al.
Blood|December 24, 2019
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control studyValerio De Stefano, Arianna Ghirardi, Arianna Masciulli, et al.
Blood Cancer Journal|March 15, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Pageof 19